Mood Disorders News

Use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors was associated with an increased risk for type 2 diabetes among Medicaid-insured youth.

Otsuka Pharmaceutical Co. and Lundbeck recently announced initiation of patient enrollment for two global phase 3 clinical trials of Rexulti for treatment of manic episodes associated with bipolar I disorder.

The FDA has approved an 80-mg capsule of Ingrezza for treatment of tardive dyskinesia in adults, according to a manufacturer-issued press release.

Galen US recently announced acquisition of U.S. commercial rights to Adasuve, an orally inhaled form of loxapine, from Alexza Pharmaceuticals for agitation associated with schizophrenia or bipolar I disorder.

NEW ORLEANS — In a session here, Rakesh Jain, MD, MPH, of Texas Tech Health Sciences Center, Midland, Texas, and Saundra Jain, MA, PsyD, LPC, of the University of Texas at Austin, weighed the benefits and risks associated with benzodiazepines.

The FDA today issued a Drug Safety Communication advising that buprenorphine and methadone should not be withheld from individuals receiving benzodiazepines or other medications that depress the central nervous system.

NEW ORLEANS — In a keynote address here at Psych Congress, Timothy S. Harlan, MD, FAPC, of Tulane University, discussed the importance of nutrition in neurocognition and mental health.

The 30th annual Psych Congress will take place in New Orleans from Saturday, Sept. 16 through Tuesday, Sept. 19.

Screening for postpartum depression in well-child care was associated with lower rates of depression and improvements in parenting, anxiety and mental health functioning when compared with usual care, concluded new data.

Teva Pharmaceuticals recently announced that the FDA approved Austedo tablets for the treatment of tardive dyskinesia in adults.